Tolerability of inhaled N-chlorotaurine in an acute pig streptococcal lower airway inflammation model

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Schwienbacher, Martin ^a   Treml, Benedikt ^a   Pinna, Anna ^a   Geiger, Ralf ^a   Reinstadler, Hannes ^a   Pircher, Iris ^a   Schmidl, Elisabeth ^a   Willomitzer, Christian ^a   Neumeister, Johannes ^a   Pilch, Michael ^a   Hauer, Maria ^a   Hager, Thomas ^b   Sergi, Consolato ^b   Scholl Bürgi, Sabine ^a   Giese, Thomas ^c,d   Löckinger, Alexander ^a   Nagl, Markus ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; HEME OXYGENASE 1; INTERLEUKIN 8; N CHLOROTAURINE; OXYGEN; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; DRUG DERIVATIVE; N-CHLOROTAURINE; TAURINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTERIAL PRESSURE; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG UPTAKE; EXPERIMENTAL PIG; GRANULOCYTE; HEMODYNAMICS; HISTOPATHOLOGY; LUNG ARTERY PRESSURE; LUNG BIOPSY; LUNG FUNCTION; LUNG GAS EXCHANGE; LUNG INFILTRATE; LUNG LAVAGE; NEBULIZATION; NONHUMAN; PROTEIN EXPRESSION; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PYOGENES; ANIMAL; BACTERIAL COUNT; BRONCHOPNEUMONIA; DISEASE MODEL; DRUG EFFECT; INHALATIONAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; STREPTOCOCCUS INFECTION; SWINE; SWINE DISEASE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-INFECTIVE AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOPNEUMONIA; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; SWINE; SWINE DISEASES; TAURINE; TREATMENT OUTCOME;

EID: 80052103387     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-231     Document Type: Article

References (25)

1. Stelmaszynska T, Zgliczynski JM. Myeloperoxidase of human neutrophilic granulocytes as chlorinating enzyme. Eur J Biochem 1974, 45:305-312. 10.1111/j.1432-1033.1974.tb03555.x, 4423007.
2. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989, 320:365-376. 10.1056/NEJM198902093200606, 2536474.
3. Gottardi W, Nagl M. Chemical properties of N-chlorotaurine sodium, a key compound in the human defence system. Arch Pharm Pharm Med Chem 2002, 335:411-421.
4. Gottardi W, Nagl M. N-chlorotaurine, a natural antiseptic with outstanding tolerability. J Antimicrob Chemother 2010, 65:399-409. 10.1093/jac/dkp466, 20053689.
5. Teuchner B, Nagl M, Schidlbauer A, Ishiko H, Dragosits E, Ulmer H, Aoki K, Ohno S, Mizuki N, Gottardi W, Larcher C. Tolerability and efficacy of N-chlorotaurine in epidemic keratoconjunctivitis - a double-blind randomized phase 2 clinical trial. J Ocular Pharmacol Ther 2005, 21:157-165.
6. Neher A, Nagl M, Appenroth E, Gstöttner M, Wischatta M, Reisigl F, Schindler M, Ulmer H, Stephan K. Acute otitis externa: efficacy and tolerability of N-chlorotaurine, a novel endogenous antiseptic agent. Laryngoscope 2004, 114:850-854. 10.1097/00005537-200405000-00011, 15126742.
7. Nagl M, Nguyen VA, Gottardi W, Ulmer H, Höpfl R. Tolerability and efficacy of N-chlorotaurine compared to chloramine T for treatment of chronic leg ulcers with purulent coating. Br J Dermatol 2003, 149:590-597. 10.1046/j.1365-2133.2003.05432.x, 14510994.
8. Geiger R, Treml B, Pinna A, Barnickel L, Prossliner H, Reinstadler H, Pilch M, Hauer M, Walther C, Steiner HJ, Giese T, Wemhöner A, Scholl-Bürgi S, Gottardi W, Arnitz R, Sergi C, Nagl M, Löckinger A. Tolerability of inhaled N-chlorotaurine in the pig model. BMC Pulmon Med 2009, 9:33.
9. Nagl M, Hess M, Pfaller K, Hengster P, Gottardi W. Bactericidal activity of micromolar N-chlorotaurine - evidence for its antimicrobial function in the human defence system. Antimicrob Agents Chemother 2000, 44:2507-2513. 10.1128/AAC.44.9.2507-2513.2000, 90093, 10952603.
10. Wagner PD, Naumann PF, Laravuso RB. Simultaneous measurement of eight foreign gases in blood by gas chromatography. J Appl Physiol 1974, 36:600-605.
11. Wagner PD, Saltzman HA, West JB. Measurement of continuous distributions of ventilation-perfusion ratios: theory. J Appl Physiol 1974, 36:588-599.
12. Weiss SJ, Klein R, Slivka A, Wei M. Chlorination of taurine by human neutrophils. J Clin Investig 1982, 70:598-607. 10.1172/JCI110652, 370261, 6286728.
13. Scholl-Bürgi S, Haberlandt E, Heinz-Erian P, Deisenhammer F, Albrecht U, Sigl SB, Rauchenzauner M, Ulmer H, Karall D. Amino acid cerebrospinal fluid/plasma ratios in children: influence of age, gender, and antiepileptic medication. Pediatrics 2008, 121:e920-e926. 10.1542/peds.2007-1631, 18332074.
14. Scholl-Bürgi S, Sass JO, Heinz-Erian P, Amann E, Haberlandt E, Albrecht U, Ertl C, Sigl SB, Lagler F, Rostasy K, Karall D. Changes in plasma amino acid concentrations with increasing age in patients with propionic acidemia. Amino Acids 2010, 38:1473-1481. 10.1007/s00726-009-0356-2, 19795187.
15. Giese T, McGrath MS, Stumm S, Schempp H, Elstner E, Meuer SC. Differential effects on innate versus adaptive immune responses by WF10. Cell Immunol 2004, 229:149-158. 10.1016/j.cellimm.2004.08.001, 15474529.
16. Luna CM, Baquero S, Gando S, Patron JR, Morato JG, Sibila O, Absi R, Famiglietti A, Vay CA, Von Stecher F, Agusti C, Torres A. Experimental severe Pseudomonas aeruginosa pneumonia and antibiotic therapy in piglets receiving mechanical ventilation. Chest 2007, 132:523-531. 10.1378/chest.07-0185, 17699131.
17. Sibila O, Agusti C, Torres A, Baquero S, Gando S, Patron JR, Morato JG, Goffredo DH, Bassi N, Luna CM. Experimental Pseudomonas aeruginosa pneumonia: evaluation of the associated inflammatory response. Eur Respir J 2007, 30:1167-1172. 10.1183/09031936.00053607, 17804447.
18. van Kaam AH, Lachmann RA, Herting E, De Jaegere A, van Iwaarden F, Noorduyn LA, Kok JH, Haitsma JJ, Lachmann B. Reducing atelectasis attenuates bacterial growth and translocation in experimental pneumonia. Am J Respir Crit Care Med 2004, 169:1046-1053. 10.1164/rccm.200312-1779OC, 14977624.
19. Lauritzen B, Lykkesfeldt J, Skaanild MT, Angen O, Nielsen JP, Friis C. Putative biomarkers for evaluating antibiotic treatment: an experimental model of porcine Actinobacillus pleuropneumoniae infection. Res Vet Sci 2003, 74:261-270. 10.1016/S0034-5288(03)00028-6, 12726745.
20. Lauritzen B, Lykkesfeldt J, Friis C. Evaluation of a single dose versus a divided dose regimen of amoxycillin in treatment of Actinobacillus pleuropneumoniae infection in pigs. Res Vet Sci 2005, 79:61-67. 10.1016/j.rvsc.2004.09.011, 15894026.
21. Nagl M, Gottardi W. Enhancement of the bactericidal efficacy of N-chlorotaurine by inflammation samples and selected N-H compounds. Hyg Med 1996, 21:597-605.
22. Nagl M, Hengster P, Semenitz E, Gottardi W. The postantibiotic effect of N-chlorotaurine on Staphylococcus aureus. Application in the mouse peritonitis model. J Antimicrob Chemother 1999, 43:805-809. 10.1093/jac/43.6.805, 10404319.
23. Nagl M, Gruber A, Fuchs A, Lell C, Lemberger EM, Borg-von Zepelin M, Wuerzner R. Impact of N-chlorotaurine on viability and production of secreted aspartyl proteinases of Candida spp. Antimicrob Agents Chemother 2002, 46:1996-1999. 10.1128/AAC.46.6.1996-1999.2002, 127226, 12019124.
24. Nagl M, Teuchner B, Pöttinger E, Ulmer H, Gottardi W. Tolerance of N-chlorotaurine, a new antimicrobial agent, in infectious conjunctivitis - a phase II pilot study. Ophthalmologica 2000, 214:111-114. 10.1159/000027477, 10720913.
25. Romanowski EG, Yates KA, Teuchner B, Nagl M, Irschick EU, Gordon YJ. N-chlorotaurine is an effective antiviral agent against adenovirus in vitro and in the Ad5/NZW rabbit ocular model. Invest Ophth Vis Sci 2006, 47:2021-2026.